Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …

Next-generation sequencing has revealed that more than 50% of human cancers harbour
mutations in enzymes that are involved in chromatin organization. Tumour cells not only are …

The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in
rapid translation of the information into clinical practice. After more than 40 years of slow …

Purpose This multicenter, randomized, open-label, phase III trial compared the efficacy and
safety of decitabine with treatment choice (TC) in older patients with newly diagnosed acute …

Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet,
an Expert Panel was selected according to the framework elements of the National Institutes …

The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid
disorders with a highly variable disease course. Diagnostic criteria to better stratify patients …

Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …

DNA hypomethylation was the initial epigenetic abnormality recognized in human tumors.
However, for several decades after its independent discovery by two laboratories in 1983, it …

Reversal of promoter DNA hypermethylation and associated gene silencing is an attractive
cancer therapy approach. The DNA methylation inhibitors decitabine and azacitidine are …

Purpose To compare low-dose decitabine to best supportive care (BSC) in higher-risk
patients with myelodysplastic syndrome (MDS) age 60 years or older and ineligible for …